Výsledky vyhledávání - Tsen‐Fang Tsai
- Zobrazuji výsledky 1 - 20 z 30
- Přejít na další stránku
-
1
Updates on the Treatment of Erythrodermic Psoriasis Autor Yang Lo, Tsen‐Fang Tsai
Vydáno 2021Revisão -
2
-
3
HLA-Cw1 and Psoriasis Autor Yi‐Wei Huang, Tsen‐Fang Tsai
Vydáno 2021Revisão -
4
-
5
-
6
-
7
-
8
How Cells Die in Psoriasis? Autor Chung-Han Chen, Nan‐Lin Wu, Tsen‐Fang Tsai
Vydáno 2025Revisão -
9
Psoriasis and Co-morbidity Autor Mina Amin, Erica B. Lee, Tsen‐Fang Tsai, Jashin J. Wu
Vydáno 2020Revisão -
10
-
11
-
12
-
13
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp>... Autor Richard Langley, Tsen‐Fang Tsai, Susan Flavin, Michael Song, B. Randazzo, Y. Wasfi, Jingzhi Jiang, S. Li, L. Puig
Vydáno 2017Artigo -
14
-
15
Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2 Autor Mark C. Genovese, B. Combe, Joel M. Kremer, Tsen‐Fang Tsai, Frank Behrens, David H. Adams, Chin Lee, Lisa Kerr, Peter Nash
Vydáno 2018Artigo -
16
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Autor Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic
Vydáno 2015Artigo -
17
Inhibition of IL‐17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections Autor Michael Kammüller, Tsen‐Fang Tsai, C.E.M. Griffiths, Nidhi Kapoor, Pappachan E. Kolattukudy, Dominique Brees, Salah‐Dine Chibout, Jorge Safi, Todd Fox
Vydáno 2017Artigo -
18
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study Autor Fernando Valenzuela, Neil J. Korman, Robert Bissonnette, Noémi Bakos, Tsen‐Fang Tsai, Melanie Harper, W.C. Ports, Huaming Tan, Anna M. Tallman, Hernán Valdez, Annie Gardner
Vydáno 2018Artigo -
19
Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study Autor Hsien‐Yi Chiu, Rosaline Chung‐Yee Hui, Yu-Huei Huang, Ruey-Yun Huang, Kai-Lung Chen, Ya‐Chu Tsai, Po-Ju Lai, Ting‐Shun Wang, Tsen‐Fang Tsai
Vydáno 2018Artigo -
20
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis Autor Akimichi Morita, Siew Eng Choon, H. Bachelez, Milan J. Anadkat, Slaheddine Marrakchi, Min Zheng, Tsen‐Fang Tsai, H. Turki, Harry Hua, Sushmita Rajeswari, Christian Thoma, A. David Burden
Vydáno 2022Artigo
Vyhledávací nástroje:
Související témata
Medicine
Psoriasis
Internal medicine
Dermatology
Psoriatic arthritis
Immunology
Pathology
Disease
Alternative medicine
Placebo
Secukinumab
Clinical trial
Adverse effect
Generalized pustular psoriasis
Randomized controlled trial
Clinical endpoint
Physics
Psoriasis Area and Severity Index
Tumor necrosis factor alpha
Ustekinumab
Adalimumab
Biology
Cohort
Cohort study
Dermatology Life Quality Index
Gastroenterology
HBsAg
Hepatitis B
Hepatitis B virus
Pustular psoriasis